Y-mAbs Omburtamab Failure The Critical Turning Point And 19.65M Shareholder Settlement
| YMAB Stock | USD 10.01 0.27 2.63% |
About 61% of Y MAbs' investor base is looking to short. The analysis of the overall investor sentiment regarding Y mAbs Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Y MAbs' historical and current headlines, can help investors time the market. In addition, many technical investors use Y mAbs Therapeutics stock news signals to limit their universe of possible portfolio assets.
YMAB |
Read at benzinga.com
 |
Y MAbs Fundamental Analysis
We analyze Y MAbs' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Y MAbs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Y MAbs based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Market Capitalization
Market Capitalization Comparative Analysis
Y MAbs is currently under evaluation in market capitalization category among its peers. Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Y mAbs Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Y MAbs stock to make a market-neutral strategy. Peer analysis of Y MAbs could also be used in its relative valuation, which is a method of valuing Y MAbs by comparing valuation metrics with similar companies.
Peers
Y MAbs Related Equities
| CCCC | C4 Therapeutics | 9.28 | ||||
| STRO | Sutro Biopharma | 4.26 | ||||
| BDTX | Black Diamond | 2.09 | ||||
| MIRM | Mirum Pharmaceuticals | 1.82 | ||||
| EWTX | Edgewise Therapeutics | 1.15 | ||||
| GBIO | Generation Bio | 0.79 | ||||
| PCVX | Vaxcyte | 0.69 | ||||
| MRUS | Merus BV | 0.58 | ||||
| TVTX | Travere Therapeutics | 0.37 | ||||
| DAWN | Day One | 0.45 | ||||
| ERAS | Erasca | 0.67 | ||||
| RVMD | Revolution Medicines | 1.82 | ||||
| MRSN | Mersana Therapeutics | 2.75 | ||||
| LRMR | Larimar Therapeutics | 2.81 | ||||
| KRON | Kronos Bio | 2.86 | ||||
| ARQT | Arcutis Biotherapeutics | 2.89 | ||||
| ZNTL | Zentalis Pharmaceuticals | 3.05 | ||||
| PASG | Passage Bio | 3.80 | ||||
| SNDX | Syndax Pharmaceuticals | 3.98 | ||||
| BLUE | Bluebird Bio | 7.14 |
Complementary Tools for YMAB Stock analysis
When running Y MAbs' price analysis, check to measure Y MAbs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Y MAbs is operating at the current time. Most of Y MAbs' value examination focuses on studying past and present price action to predict the probability of Y MAbs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Y MAbs' price. Additionally, you may evaluate how the addition of Y MAbs to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |